What is it about?
CYFRA 21-1 is a prognostic marker for non-small cell lung cancer (NSCLC). The serum CYFRA 21-1 level is also known as an adjunct for the diagnosis of lung squamous cell carcinoma. We hypothesized that a high serum CYFRA 21-1 level is correlated with a greater efficacy of nivolumab therapy in lung adenocarcinoma patients. In the present study, we investigated the predictive implications of the CYFRA 21-1 level in advanced lung adenocarcinoma patients treated with nivolumab therapy.
Featured Image
Why is it important?
A CYFRA 21-1 level lower than the cutoff value predicts a favorable outcome among patients with EGFR-mutated NSCLC who are treated with an EGFR-TKI and among patients with lung adenocarcinoma. In the present study, however, a CYFRA 21-1 level higher than the cutoff value has been reported to predict a favorable outcome among patients with lung adenocarcinoma who were treated with nivolumab.
Perspectives
A serum CYFRA 21-1 level ≥ 2.2 ng/mL was regarded as a predictor of the efficacy of nivolumab therapy in lung adenocarcinoma patients. In daily clinical practice, evaluating the serum CYFRA 21-1 level (≥ 2.2 ng/mL) might be clinically relevant in adenocarcinoma patients treated with nivolumab therapy.
Dr Akira Ono
Shizuoka Cancer Center
Read the Original
This page is a summary of: CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma, Tumor Biology, February 2018, SAGE Publications,
DOI: 10.1177/1010428318760420.
You can read the full text:
Contributors
The following have contributed to this page
